H.C. Wainwright maintains USD 152.00 target for Incyte stock

Published on 10/20/2026 at 20:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Truist raised its target to USD 115.00 on October 14, 2026. Incyte stock costs EUR 103.60 on October 20, 2026 at 8:36 p.m. CEST.

Analyst targets and reporting date

H.C. Wainwright maintained a USD 152.00 target and Buy rating on October 16, 2026.
Truist raised its target from USD 105.00 to USD 115.00 on October 14, 2026.
Incyte stock cost EUR 103.60 at Lang & Schwarz on October 20, 2026 at 8:36 p.m. CEST.
Incyte will publish third-quarter results on October 29, 2026.

Schwarzweiß-Dokumentarfoto einer Forscherin mit Laborampullen — Incyte Forscherin prüft Reagenzgläser in Schwarzweiß-Reportage, dokumentarisches Symbol für ISIN US45337C1027 Biotechnologie, Illustration mit AI erstellt.

H.C. Wainwright maintained a Buy rating and a USD 152.00 price target for Incyte on October 16, 2026, keeping the analyst focus on the company's late-stage pipeline. According to Investing.com, the firm linked its view to clinical data around KRAS G12D programs. Incyte was trading at EUR 103.60 at Lang & Schwarz on October 20, 2026 at 8:36 p.m. CEST.

Analyst targets move higher

The latest target follows several upward revisions in October. Truist analyst Srikripa Devarakonda raised the target from USD 105.00 to USD 115.00 while keeping a Hold rating, according to Markets Insider on October 14, 2026. Stifel had raised its target from USD 145.00 to USD 157.00 on October 5, 2026, while UBS moved its target from USD 113.00 to USD 127.00, as reported by Investing.com.

Stock position and valuation

On Nasdaq, Incyte last traded at USD 116.29 on October 20, 2026 at 2:39 p.m. ET. The price was 30.71 percent below the H.C. Wainwright target of USD 152.00, calculated from the two USD prices. Its 52-week range was USD 84.02 to USD 132.60, placing the Nasdaq price USD 16.31 below the high and USD 32.27 above the low.

Results date is October 29

Incyte has scheduled its third-quarter financial results for October 29, 2026. The release is set for 7:00 a.m. ET, followed by the conference call at 8:00 a.m. ET, according to MarketScreener. The date gives investors a defined near-term event after the October target revisions.

Comparison with peers

Incyte: 14.82 price-to-earnings ratio, USD 23.6 billion market capitalization. Bristol-Myers Squibb (NYSE, USD): 13.55 price-to-earnings ratio, USD 125.6 billion market capitalization. Regeneron Pharmaceuticals (Nasdaq, USD): 19.75 price-to-earnings ratio, USD 82.2 billion market capitalization.

Targets and results shape the setup

The analyst range remains wide, from Truist's USD 115.00 to Stifel's USD 157.00, while H.C. Wainwright's USD 152.00 target sits near the upper end. The October 29 results therefore provide the next scheduled test for the estimates and the pipeline narrative.

The further course of trading is shown by the continuously updated real-time quote of Incyte stock.